There has been a tremendous amount of speculation surrounding the potential adverse effect of angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARS) in CVD patients with COVID-19. This evidence concerns the gene ACE and COVID-19.